Skip to main content
Shop Plans Learn more about our coverage options including health, Medicare, dental and vision options for you, your family or your employees. Get Started Individual & Family Medicare Employer Vision Dental International Travel Find Care FAQ Blog Members Stay on top of your health care with helpful member resources. Members Home Medicare Health Dental Vision Find Care Member Knowledge Center Member Forms Medicare Forms Library Make a Payment Federal Employees Student Blue Healthy Blue Providers Access tools, policies and the latest information to help you care for our members. Providers Home Network Participation Networks & Programs Claims, Appeals & Inquiries Prior Authorization Services & CPT codes Prescription Drug Search Policies, Guidelines & Codes Provider News Provider FAQ Contact Us Employers Learn about our coverage options for small and large employers, and access tools and resources for your group. Employers Home Shop Employer Plans Employer Portal Support Member Forms & Resources Find Care Blog Agents Access the tools you need: rate quotes, applications, forms, the latest industry news, marketing materials and more. Agents Home Agent Services Check Eligibility Find Care Member Forms & Resources Medicare Forms Library
Contact Us
Log In
I am ... Please select A member A provider An employer An agent
Log in to Agent Services
Log in to Employer Services Register for Employer Services I'm registered but need portal access
Username Forgot username? Continue to Log In Register for Blue Connect Need help? Learn how to log in.
Log in to Blue e Register for Blue e Log in to Dental Blue
Back
Notification of Drug Policy Revisions Effective July 1, 2023 (Posted April 1, 2023) April 01, 2023
Medical GuidelinesReason for Update
Gonadotropin Releasing Hormone Therapy Original medical policy criteria issued. Policy notification given 4/1/2023 for effective date 7/1/2023.
Injectable and Healthcare Administered Oncology Drugs Added Pemfexy (pemetrexed) for treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and for treatment of malignant pleural mesothelioma in patients whose disease is unresectable or who are otherwise not candidates for curative surgery, and added HCPCS code J9304 and associated dosing to FDA label reference table. Removed Blenrep (belantamab mafodotin-blmf) from policy due to FDA market withdrawal based on the confirmatory clinical trial not meeting requirements of FDA Accelerated Approval regulations; Blenrep is now only available for continued use through the manufacturer’s compassionate use program. Removed Zoladex (goserelin) from policy and added it to a separate individual policy (Gonadotropin Releasing Hormone Therapy). Policy notification given 4/1/2023 for effective date 7/1/2023.